JP2005523309A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005523309A5 JP2005523309A5 JP2003583368A JP2003583368A JP2005523309A5 JP 2005523309 A5 JP2005523309 A5 JP 2005523309A5 JP 2003583368 A JP2003583368 A JP 2003583368A JP 2003583368 A JP2003583368 A JP 2003583368A JP 2005523309 A5 JP2005523309 A5 JP 2005523309A5
- Authority
- JP
- Japan
- Prior art keywords
- dosage form
- antibiotic
- product
- max
- dosage
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000002552 dosage form Substances 0.000 claims 54
- 230000003115 biocidal effect Effects 0.000 claims 32
- 239000003242 anti bacterial agent Substances 0.000 claims 10
- 229940088710 antibiotic agent Drugs 0.000 claims 8
- 210000002966 serum Anatomy 0.000 claims 6
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 claims 4
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 claims 4
- 230000003111 delayed effect Effects 0.000 claims 4
- SGKRLCUYIXIAHR-AKNGSSGZSA-N (4s,4ar,5s,5ar,6r,12ar)-4-(dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1=CC=C2[C@H](C)[C@@H]([C@H](O)[C@@H]3[C@](C(O)=C(C(N)=O)C(=O)[C@H]3N(C)C)(O)C3=O)C3=C(O)C2=C1O SGKRLCUYIXIAHR-AKNGSSGZSA-N 0.000 claims 2
- 229930186147 Cephalosporin Natural products 0.000 claims 2
- -1 Fururokiniron Chemical compound 0.000 claims 2
- GSDSWSVVBLHKDQ-JTQLQIEISA-N Levofloxacin Chemical compound C([C@@H](N1C2=C(C(C(C(O)=O)=C1)=O)C=C1F)C)OC2=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-JTQLQIEISA-N 0.000 claims 2
- 229930182555 Penicillin Natural products 0.000 claims 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 claims 2
- 239000004098 Tetracycline Substances 0.000 claims 2
- 229960003022 amoxicillin Drugs 0.000 claims 2
- LSQZJLSUYDQPKJ-NJBDSQKTSA-N amoxicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 LSQZJLSUYDQPKJ-NJBDSQKTSA-N 0.000 claims 2
- 229960005090 cefpodoxime Drugs 0.000 claims 2
- WYUSVOMTXWRGEK-HBWVYFAYSA-N cefpodoxime Chemical compound N([C@H]1[C@@H]2N(C1=O)C(=C(CS2)COC)C(O)=O)C(=O)C(=N/OC)\C1=CSC(N)=N1 WYUSVOMTXWRGEK-HBWVYFAYSA-N 0.000 claims 2
- 229960001668 cefuroxime Drugs 0.000 claims 2
- JFPVXVDWJQMJEE-IZRZKJBUSA-N cefuroxime Chemical compound N([C@@H]1C(N2C(=C(COC(N)=O)CS[C@@H]21)C(O)=O)=O)C(=O)\C(=N/OC)C1=CC=CO1 JFPVXVDWJQMJEE-IZRZKJBUSA-N 0.000 claims 2
- 229940124587 cephalosporin Drugs 0.000 claims 2
- 150000001780 cephalosporins Chemical class 0.000 claims 2
- 229960003405 ciprofloxacin Drugs 0.000 claims 2
- 229960002626 clarithromycin Drugs 0.000 claims 2
- AGOYDEPGAOXOCK-KCBOHYOISA-N clarithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@](C)([C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)OC)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 AGOYDEPGAOXOCK-KCBOHYOISA-N 0.000 claims 2
- 229960001585 dicloxacillin Drugs 0.000 claims 2
- YFAGHNZHGGCZAX-JKIFEVAISA-N dicloxacillin Chemical compound N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C(O)=O)=O)C(=O)C1=C(C)ON=C1C1=C(Cl)C=CC=C1Cl YFAGHNZHGGCZAX-JKIFEVAISA-N 0.000 claims 2
- 229960003722 doxycycline Drugs 0.000 claims 2
- 229960003276 erythromycin Drugs 0.000 claims 2
- 239000012729 immediate-release (IR) formulation Substances 0.000 claims 2
- 229960003376 levofloxacin Drugs 0.000 claims 2
- 229960000282 metronidazole Drugs 0.000 claims 2
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 claims 2
- LSQZJLSUYDQPKJ-UHFFFAOYSA-N p-Hydroxyampicillin Natural products O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)C(N)C1=CC=C(O)C=C1 LSQZJLSUYDQPKJ-UHFFFAOYSA-N 0.000 claims 2
- 229940049954 penicillin Drugs 0.000 claims 2
- 229960002180 tetracycline Drugs 0.000 claims 2
- 229930101283 tetracycline Natural products 0.000 claims 2
- 235000019364 tetracycline Nutrition 0.000 claims 2
- 150000003522 tetracyclines Chemical class 0.000 claims 2
- 208000035143 Bacterial infection Diseases 0.000 claims 1
- 208000022362 bacterial infectious disease Diseases 0.000 claims 1
- 239000003782 beta lactam antibiotic agent Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000002132 β-lactam antibiotic Substances 0.000 claims 1
- 229940124586 β-lactam antibiotics Drugs 0.000 claims 1
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/027,866 US6663890B2 (en) | 2000-02-24 | 2001-12-20 | Metronidazole antibiotic product, use and formulation thereof |
US10/027,366 US6667057B2 (en) | 2000-02-24 | 2001-12-20 | Levofloxacin antibiotic product, use and formulation thereof |
US10/027,609 US6669948B2 (en) | 2000-02-24 | 2001-12-20 | Antibiotic product, use and formulation thereof |
US10/028,595 US6663891B2 (en) | 2000-02-24 | 2001-12-20 | Erythromyacin antibiotic product, use and formulation thereof |
US10/028,590 US6730320B2 (en) | 2000-02-24 | 2001-12-20 | Tetracycline antibiotic product, use and formulation thereof |
US10/027,837 US6667042B2 (en) | 2000-02-24 | 2001-12-20 | Fluroquinilone antibiotic product, use and formulation thereof |
PCT/US2002/040809 WO2003086344A1 (fr) | 2001-12-20 | 2002-12-20 | Produit antibiotique, son utilisation et sa formulation |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2005523309A JP2005523309A (ja) | 2005-08-04 |
JP2005523309A5 true JP2005523309A5 (fr) | 2006-02-16 |
Family
ID=29255716
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2003583368A Withdrawn JP2005523309A (ja) | 2001-12-20 | 2002-12-20 | 抗生物質産物、その使用法と製剤 |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP1465591A1 (fr) |
JP (1) | JP2005523309A (fr) |
AU (1) | AU2002359768A1 (fr) |
CA (1) | CA2470016A1 (fr) |
WO (1) | WO2003086344A1 (fr) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6544555B2 (en) | 2000-02-24 | 2003-04-08 | Advancis Pharmaceutical Corp. | Antibiotic product, use and formulation thereof |
US20020068078A1 (en) | 2000-10-13 | 2002-06-06 | Rudnic Edward M. | Antifungal product, use and formulation thereof |
WO2005009365A2 (fr) * | 2003-07-21 | 2005-02-03 | Advancis Pharmaceutical Corporation | Produit antibiotique, son utilisation et sa formulation |
PT1883396E (pt) | 2005-05-18 | 2013-10-08 | Centre Nat Rech Scient | Administração colónica de adsorventes |
US8778924B2 (en) | 2006-12-04 | 2014-07-15 | Shionogi Inc. | Modified release amoxicillin products |
US8048413B2 (en) | 2006-05-17 | 2011-11-01 | Helene Huguet | Site-specific intestinal delivery of adsorbents, alone or in combination with degrading molecules |
JP5318400B2 (ja) * | 2006-11-20 | 2013-10-16 | 第一三共株式会社 | レボフロキサシン含有錠剤 |
JP5788142B2 (ja) * | 2006-12-04 | 2015-09-30 | シオノギ インコーポレイテッド | 変性放出アモキシシリン製剤 |
US20130259947A1 (en) * | 2010-11-29 | 2013-10-03 | Dr. Reddy's Laboratories Ltd. | Oral metronidazole pharmaceutical compositions |
US9119793B1 (en) | 2011-06-28 | 2015-09-01 | Medicis Pharmaceutical Corporation | Gastroretentive dosage forms for doxycycline |
GB201210184D0 (en) * | 2012-06-11 | 2012-07-25 | Univ Leuven Kath | Formulations of metronidazole for the treatment of pouchitis |
US10842802B2 (en) | 2013-03-15 | 2020-11-24 | Medicis Pharmaceutical Corporation | Controlled release pharmaceutical dosage forms |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5011692A (en) * | 1985-12-28 | 1991-04-30 | Sumitomo Pharmaceuticals Company, Limited | Sustained pulsewise release pharmaceutical preparation |
US4794001A (en) * | 1986-03-04 | 1988-12-27 | American Home Products Corporation | Formulations providing three distinct releases |
US5260069A (en) * | 1992-11-27 | 1993-11-09 | Anda Sr Pharmaceuticals Inc. | Pulsatile particles drug delivery system |
IL119627A (en) * | 1996-11-17 | 2002-03-10 | Yissum Res Dev Co | PHARMACEUTICAL PREPARATIONS FOR THE CONTROLLED-RELEASE OF AN ACTIVE AGENT COMPRISING AT LEAST ONE β-LACTAM ANTIBIOTIC AGENT |
-
2002
- 2002-12-20 EP EP20020794328 patent/EP1465591A1/fr not_active Withdrawn
- 2002-12-20 JP JP2003583368A patent/JP2005523309A/ja not_active Withdrawn
- 2002-12-20 CA CA002470016A patent/CA2470016A1/fr not_active Abandoned
- 2002-12-20 WO PCT/US2002/040809 patent/WO2003086344A1/fr active Application Filing
- 2002-12-20 AU AU2002359768A patent/AU2002359768A1/en not_active Abandoned
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2005523309A5 (fr) | ||
Berlucchi et al. | Update on treatment of Marshall's syndrome (PFAPA syndrome): report of five cases with review of the literature | |
JP2006528699A5 (fr) | ||
DE69735093D1 (de) | ARZNEIMITTEL ZUR GESTEUERTEN FREISETZUNG VON beta LACTAM ANTIBIOTIKA | |
JP2004502752A5 (fr) | ||
ES2122810T3 (es) | Formulacion de liberacion controlada para medicamentos basicos poco solubles. | |
EP1270005A3 (fr) | Formulation comprenant de l'amoxicilline et un acide organique | |
BR0112532A (pt) | Composição farmacêutica oral, sistema galênico e uso da composição | |
EP2260870A2 (fr) | Traitement de maladies infectieuse par des mélanges de dérivés de thioxanthène avec des agents anti-infectieux | |
JPH0692850A (ja) | 胃腸障害治療薬 | |
MX2011002185A (es) | Composiciones y metodos de tratamiento que comprenden ceftarolina. | |
WO2005030109A3 (fr) | Schema posologique pour l'administration d'antibiotiques de la classe des rifamycines | |
Jewesson | Pharmaceutical, pharmacokinetic and other considerations for intravenous to oral stepdown therapy | |
Centers for Disease Control and Prevention (CDC | Updated recommendations for antimicrobial prophylaxis among asymptomatic pregnant women after exposure to Bacillus anthracis | |
DiPersio et al. | Fluoroquinolone-resistant Moraxella catarrhalis in a patient with pneumonia: report from the SENTRY Antimicrobial Surveillance Program (1998) | |
JP2011502103A (ja) | カルバペネム類を含む殺菌性抗mrsa活性医薬組成物 | |
PICHICHERO | Therapeutic considerations for management of otitis media, sinusitis, and tonsillopharyngitis | |
WO2017209588A3 (fr) | Formulation pharmaceutique de cinéol et d'amoxicilline | |
JP2006528189A5 (fr) | ||
JP2006528190A5 (fr) | ||
DK1461017T3 (da) | Farmaceutisk sammensætning til styret frigivelse af et beta-lactam-antibiotikum | |
JP2006528185A5 (fr) | ||
JP2007502294A5 (fr) | ||
CN101505740A (zh) | 改进的细菌感染治疗方法 | |
EP0911030A3 (fr) | Compositions antimicrobiennes contenant des dérivés de vinylpyrrolidinone-céphalosporine et un antibiotique carbapénème ou un inhibiteur du béta-lactamase |